We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+41.81%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$368M
AUM Growth
+$22.1M
Cap. Flow
-$24.9M
Cap. Flow %
-6.76%
Top 10 Hldgs %
54.53%
Holding
62
New
16
Increased
11
Reduced
11
Closed
19

Top Buys

Rank Stock Value
1
CMPS
Compass Pathways
CMPS
+$14M
2
ETNB
89bio
ETNB
+$13.2M
3
SAGE
Sage Therapeutics
SAGE
+$11.4M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$8.5M
5
CYTK icon
Cytokinetics
CYTK
+$8.36M

Top Sells

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$36.5M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$18.1M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$11.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.43M
5
ASND icon
Ascendis Pharma A/S
ASND
+$8.21M

Sector Composition

Rank Sector Weight
1 Healthcare 73.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$43.5M 11.81%
511,500
-33,500
-6% -$1.69M
KURA icon
2
Kura Oncology
KURA
$816M
$29.8M 8.1%
973,000
+100,500
+12% +$2.22M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$27.9M 7.57%
+250,000
New +$28M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.96B
$22.9M 6.22%
1,545,000
+545,000
+55% +$6.38M
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$13.8M 3.73%
+225,000
New +$11.4M
CMPS
6
Compass Pathways
CMPS
$1.52B
$13.6M 3.7%
+390,000
New +$14M
LRMR icon
7
Larimar Therapeutics
LRMR
$413M
$12.6M 3.42%
830,000
+6,831
+0.8% +$86.5K
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$12.4M 3.38%
26,700
+1,400
+6% +$707K
ALDX icon
9
Aldeyra Therapeutics
ALDX
$92.3M
$12.2M 3.31%
1,646,700
+756,700
+85% +$4.89M
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
$12.1M 3.29%
+853,000
New +$8.5M
ETNB
11
DELISTED
89bio
ETNB
$10.7M 2.91%
+417,500
New +$13.2M
RLMD icon
12
Relmada Therapeutics
RLMD
$556M
$10.4M 2.83%
277,000
+42,500
+18% +$1.64M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$1.93B
$10.4M 2.82%
315,000
-275,000
-47% -$8.43M
ALT icon
14
Altimmune
ALT
$583M
$9.08M 2.47%
688,000
+150,500
+28% +$3.01M
IMVT icon
15
Immunovant
IMVT
$7.91B
$8.8M 2.39%
250,000
-100,000
-29% -$3.01M
CYTK icon
16
Cytokinetics
CYTK
$10.4B
$7.74M 2.1%
+357,500
New +$8.36M
RAPT
17
DELISTED
RAPT Therapeutics
RAPT
$7.73M 2.1%
+30,000
New +$6.66M
LSACU
18
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$7.62M 2.07%
560,000
– –
SURF
19
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$7.51M 2.04%
1,088,000
+863,000
+384% +$5.24M
LONA
20
LeonaBio Inc
LONA
$70.2M
$6.69M 1.82%
+36,250
New +$6.05M
RNAM
21
DELISTED
Avidity Biosciences
RNAM
$6.62M 1.8%
235,000
+117,500
+100% +$3.4M
GYRE icon
22
Gyre Therapeutics
GYRE
$681M
$6.44M 1.75%
199,720
– –
RNAC icon
23
Cartesian Therapeutics
RNAC
$231M
$5.86M 1.59%
78,807
– –
CBAY
24
DELISTED
Cymabay Therapeutics
CBAY
$5.54M 1.5%
+765,000
New +$4.09M
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
$5.04M 1.37%
167,054
-22,946
-12% -$686K
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Acuta Capital Partners held 62 positions worth $368M, up 6.4% from $346M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Acuta Capital Partners withdrew a net $24.9M in Q3 2020, closing 19 positions and reducing 11 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Compass Pathways worth $13.6M.

  • Acuta Capital Partners's largest Q3 2020 buy was Compass Pathways: 390,000 shares worth $13.6M.
  • Acuta Capital Partners added most to Celldex Therapeutics in Q3 2020, an estimated $6.38M increase.
  • Acuta Capital Partners's biggest Q3 2020 reduction was Iovance Biotherapeutics, cutting an estimated $8.43M.
  • Acuta Capital Partners fully exited Adverum Biotechnologies in Q3 2020, selling an estimated $36.5M.
  • Acuta Capital Partners's ten largest holdings make up 55% of its $368M portfolio in Q3 2020.
  • Acuta Capital Partners opened 16 new positions and closed 19 in Q3 2020.
  • Acuta Capital Partners's portfolio value rose 6.4% quarter-over-quarter to $368M.

Based on Acuta Capital Partners's 13F filing for Q3 2020, filed 16 Nov 2020.